Amgen Inc. (NASDAQ:AMGN) and Kyowa Kirin released preliminary topline results from the ASCEND study evaluating rocatinlimab ...

Amgen and Kyowa Kirin announced preliminary top-line results from the ASCEND study, evaluating the investigational therapy ...

Jefferies analysts expect a regulatory filing for rocatinlimab later this year, with a product launch in 2026.

Rocatinlimab is also being studied for moderate to severe uncontrolled asthma, prurigo nodularis and potentially other conditions where T-cell imbalance is a root cause of inflammation. The initial ...

Amgen (AMGN) and Kyowa Kirin Co., Ltd. announced promising preliminary results from their ASCEND study, focusing on a new ...

Across the Phase 3 ROCKET program including ASCEND, the incidence of gastrointestinal ulceration events with rocatinlimab to date is less than 1 per 100 patient-years. The ASCEND study is ongoing and ...

A mgen and Kyowa Kirin have announced initial top-line findings from the Phase III ASCEND trial assessing the investigational ...

Amgen (NASDAQ:AMGN) and Kyowa Kirin (OTCPK:KYKOF) announced on Tuesday that their antibody therapy rocatinlimab is safe and ...

Results from the Phase III ASCEND trial (NCT05882877) showed rocatinlimab maintained long-term efficacy with a favorable ...

On September 9, Seema Shah, Chief Global Strategist at Principal Asset Management, appeared on CNBC for an interview to ...

William Blair notes OX40 antibodies rocatinlimab and amlitelimab trail Dupixent in efficacy, with dosing and side effects ...

Amgen & Kyowa Kirin announce positive results from rocatinlimab phase 3 ASCEND study in adults with moderate to severe atopic dermatitis: Thousand Oaks, California Wednesday, Sept ...